|
CELLERANT THERAPEUTICS AWARDED ADDITIONAL $16.7 MILLION UNDER EXISTING US GOVERNMENT CONTRACT TO FUND DEVELOPMENT OF CLT-008 FOR ACUTE RADIATION SYNDROME
September 15, 2011
CELLERANT THERAPEUTICS INITIATES A PHASE I/II CLINICAL TRIAL OF CLT-008 FOR CHEMOTHERAPY INDUCED NEUTROPENIA IN ACUTE LEUKEMIA PATIENTS
March 22, 2011
CELLERANT THERAPEUTICS ANNOUNCES KEY ADDITIONS TO SR. MANAGEMENT TEAM
February 7, 2011
|
